HRP20141217T1 - G-csf tekuä†a formulacija - Google Patents
G-csf tekuä†a formulacija Download PDFInfo
- Publication number
- HRP20141217T1 HRP20141217T1 HRP20141217AT HRP20141217T HRP20141217T1 HR P20141217 T1 HRP20141217 T1 HR P20141217T1 HR P20141217A T HRP20141217A T HR P20141217AT HR P20141217 T HRP20141217 T HR P20141217T HR P20141217 T1 HRP20141217 T1 HR P20141217T1
- Authority
- HR
- Croatia
- Prior art keywords
- csf
- concentration
- pharmaceutical preparation
- preparation according
- container
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 9
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 150000005846 sugar alcohols Chemical class 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003708 ampul Substances 0.000 claims 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 239000003978 infusion fluid Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- -1 polytetrafluoroethylene Polymers 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (18)
1. Farmaceutski pripravak za uporabu u liječenju raka, teške kronične neutropenije (SCN), infekcije HIV-om, oštećenja središnjeg živčanog sustava ili u liječenju štetnih nuspojava kod citoksične kemoterapije koja sadrži G-CSF tekuću formulaciju, te se uglavnom sastoji od G-CSF-a i šećernog alkohola, polisorbata 80 u koncentraciji od 0.05-0.06 mg/ml, acetata u koncentraciji od 5-20 mM, kao pufera pri pH od 4.15-4.3, a po potrebi i od aminokiselina i/ili glicerola i/ili ugljikohidrata i/ili konzervansa, naznačen time, da se acetat dodaje u obliku njegove octene kiseline i da se pH podešava s NaOH.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da G- CSF nije glikoziliran.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je G-CSF prisutan u koncentraciji od 0.6 mg / ml.
4. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je šećerni alkohol sorbitol.
5. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da je šećerni alkohol prisutan u koncentraciji od 5% (w/v).
6. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da je acetat prisutan u koncentraciji od 10 mM.
7. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je u biti bez aminokiselina i/ili dodatnog proteina.
8. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da je u obliku injekcijske ili infuzijske otopine.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 1 u obliku injekcijske ili infuzijske otopine, naznačen time, da je G-CSF ljudski, neglikolizirani metionil G-CSF, prisutan u koncentraciji od 0.6 mg/ml, šećerni alkohol je sorbitol koji je prisutan u koncentraciji od 5% (w/v), površinski aktivna tvar (surfaktant) je polisorbat 80, a acetat je prisutan kao pufer u koncentraciji od 10 mM.
10. Spremnik za primjenu tekućih farmaceutskih pripravaka, naznačen time, da sadrži tekuću formulaciju farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
11. Spremnik u skladu s patentnim zahtjevom 10, naznačen time, da je najmanje jedna površina navedenog spremnika, koja je u kontaktu s tekućom formulacijom prevučena s materijalom koji se sastoji od silikona ili politetrafluoretilena ili etilentetrafluoretilen (ETFE) kopolimera.
12. Spremnik u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da je spremnik sa štrcaljkom, ampulom, karpulom ili spremnikom za infuziju.
13. Štrcaljka ili ampula u skladu s patentnim zahtjevom 12, naznačena tme, da sadrži tekući pripravak koji se odnosi na koncentraciju G-CSF-a, pri koncentraciji od 0.3 mg u 0.5 ml ili 0.48 mg u 0,8 ml.
14. Oprema za parenteralnu primjenu G-CSF-a, naznačena time, da sadrži spremnik u skladu s bilo kojim od patentnih zahtjeva 10 do 13, kao i upute za skladištenje i/ili korištenje.
15. Oprema u skladu s patentnim zahtjevom 14, naznačena time, da je primjena G-CSF omogućena u doziranju od 5-30 μg/kg tjelesne težine.
16. Oprema u skladu s patentnim zahtjevom 14 ili 15, naznačena time, da sadrži 5 štrcaljki ili ampula u navedenom kompletu.
17. Oprema u skladu s bilo kojim od patentnih zahtjeva 14 do 16, naznačena time, da sadrži sigurnosne odjeljke za štrcaljke ili injekcije i/ili za infuzijske igle.
18. Oprema u skladu s bilo kojim od patentnih zahtjeva 14 do 17, naznačena time, da je namijenjena za pohranjivanje na 5°C.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007040932A DE102007040932A1 (de) | 2007-08-27 | 2007-08-27 | Flüssigformulierung von G-CSF |
| EP07016763 | 2007-08-27 | ||
| PCT/EP2008/007012 WO2009027076A1 (de) | 2007-08-27 | 2008-08-27 | Flüssigformulierung von g-csf |
| EP08785714.0A EP2076243B9 (de) | 2007-08-27 | 2008-08-27 | Flüssigformulierung von g-csf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141217T1 true HRP20141217T1 (hr) | 2015-02-27 |
Family
ID=39745039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141217AT HRP20141217T1 (hr) | 2007-08-27 | 2014-12-16 | G-csf tekuä†a formulacija |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8562967B2 (hr) |
| EP (2) | EP2076243B9 (hr) |
| JP (2) | JP2010536906A (hr) |
| KR (1) | KR20100044261A (hr) |
| CN (1) | CN101795670A (hr) |
| AU (1) | AU2008291309B2 (hr) |
| BR (1) | BRPI0815280A2 (hr) |
| CA (1) | CA2697376C (hr) |
| CY (1) | CY1115815T1 (hr) |
| DK (1) | DK2076243T3 (hr) |
| ES (1) | ES2524454T3 (hr) |
| HR (1) | HRP20141217T1 (hr) |
| IL (1) | IL204118A (hr) |
| MX (1) | MX2010002348A (hr) |
| NZ (1) | NZ583999A (hr) |
| PL (1) | PL2076243T3 (hr) |
| PT (1) | PT2076243E (hr) |
| SI (1) | SI2076243T1 (hr) |
| UA (1) | UA100245C2 (hr) |
| WO (1) | WO2009027076A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2399572A1 (en) * | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
| AU2015231278B2 (en) * | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| US11896037B2 (en) | 2016-08-03 | 2024-02-13 | Temple University-Of The Commonwealth System Of Higher Education | Microencapsulation of active agents |
| ES2882181T3 (es) * | 2016-10-31 | 2021-12-01 | Fresenius Kabi Deutschland Gmbh | Composición farmacéutica líquida |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
| NZ236819A (en) | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
| CA2082951C (en) * | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
| DE4126983A1 (de) | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| DE4242863A1 (de) | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| EP1060746A4 (en) | 1998-03-06 | 2002-06-19 | Chugai Pharmaceutical Co Ltd | PROTEIN-FREE PREPARATIONS |
| ES2216447T3 (es) | 1998-08-17 | 2004-10-16 | Pfizer Products Inc. | Composiciones proteicas estabilizadas. |
| DK1129720T3 (da) | 2000-02-29 | 2004-09-27 | Pfizer Prod Inc | Stabiliseret granulocyt-kolonistimulerende faktor |
| AU2002345829A1 (en) | 2002-06-24 | 2004-01-06 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
| DE10348550A1 (de) * | 2003-10-20 | 2005-06-16 | Hexal Biotech Forschungsgmbh | Stabile wässrige G-CSF-haltige Zusammensetzungen |
| WO2005042024A1 (en) | 2003-11-04 | 2005-05-12 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising granulocyte-colony stimulating factor |
| DE102006009437A1 (de) | 2006-03-01 | 2007-09-13 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
-
2008
- 2008-08-27 EP EP08785714.0A patent/EP2076243B9/de active Active
- 2008-08-27 UA UAA201002405A patent/UA100245C2/uk unknown
- 2008-08-27 DK DK08785714.0T patent/DK2076243T3/da active
- 2008-08-27 KR KR20107005783A patent/KR20100044261A/ko active Search and Examination
- 2008-08-27 AU AU2008291309A patent/AU2008291309B2/en not_active Ceased
- 2008-08-27 ES ES08785714.0T patent/ES2524454T3/es active Active
- 2008-08-27 SI SI200831345T patent/SI2076243T1/sl unknown
- 2008-08-27 US US12/675,776 patent/US8562967B2/en not_active Expired - Fee Related
- 2008-08-27 CN CN200880105177A patent/CN101795670A/zh active Pending
- 2008-08-27 JP JP2010522242A patent/JP2010536906A/ja active Pending
- 2008-08-27 PL PL08785714T patent/PL2076243T3/pl unknown
- 2008-08-27 EP EP20120162063 patent/EP2471510A1/de not_active Withdrawn
- 2008-08-27 NZ NZ583999A patent/NZ583999A/en not_active IP Right Cessation
- 2008-08-27 WO PCT/EP2008/007012 patent/WO2009027076A1/de active Application Filing
- 2008-08-27 BR BRPI0815280-2A patent/BRPI0815280A2/pt not_active Application Discontinuation
- 2008-08-27 PT PT08785714T patent/PT2076243E/pt unknown
- 2008-08-27 MX MX2010002348A patent/MX2010002348A/es active IP Right Grant
- 2008-08-27 CA CA2697376A patent/CA2697376C/en not_active Expired - Fee Related
-
2010
- 2010-02-23 IL IL204118A patent/IL204118A/en active IP Right Grant
-
2013
- 2013-10-02 US US14/044,852 patent/US8946161B2/en not_active Expired - Fee Related
-
2014
- 2014-10-02 JP JP2014203721A patent/JP2015038111A/ja active Pending
- 2014-12-12 CY CY20141101037T patent/CY1115815T1/el unknown
- 2014-12-16 HR HRP20141217AT patent/HRP20141217T1/hr unknown
-
2015
- 2015-01-09 US US14/593,862 patent/US9468685B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2524454T3 (es) | 2014-12-09 |
| US8946161B2 (en) | 2015-02-03 |
| JP2015038111A (ja) | 2015-02-26 |
| US9468685B2 (en) | 2016-10-18 |
| EP2471510A1 (de) | 2012-07-04 |
| WO2009027076A1 (de) | 2009-03-05 |
| PT2076243E (pt) | 2014-12-05 |
| NZ583999A (en) | 2011-10-28 |
| EP2076243B9 (de) | 2015-01-14 |
| CA2697376C (en) | 2016-07-19 |
| SI2076243T1 (sl) | 2015-01-30 |
| US20150125420A1 (en) | 2015-05-07 |
| AU2008291309B2 (en) | 2013-10-17 |
| CN101795670A (zh) | 2010-08-04 |
| EP2076243B1 (de) | 2014-10-01 |
| US20100216698A1 (en) | 2010-08-26 |
| JP2010536906A (ja) | 2010-12-02 |
| EP2076243A1 (de) | 2009-07-08 |
| CY1115815T1 (el) | 2017-01-25 |
| IL204118A (en) | 2014-11-30 |
| US8562967B2 (en) | 2013-10-22 |
| AU2008291309A1 (en) | 2009-03-05 |
| KR20100044261A (ko) | 2010-04-29 |
| CA2697376A1 (en) | 2009-03-05 |
| US20140030214A1 (en) | 2014-01-30 |
| PL2076243T3 (pl) | 2015-04-30 |
| BRPI0815280A2 (pt) | 2018-11-27 |
| DK2076243T3 (da) | 2015-01-05 |
| MX2010002348A (es) | 2010-07-30 |
| UA100245C2 (uk) | 2012-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191923T1 (hr) | Postupci i sastavi za isporuku arilsulfataze a u cns | |
| ES2471942T3 (es) | Formulaciones líquidas de interfer�n beta estabilizadas en recipientes farmacéuticos revestidos | |
| US8084420B2 (en) | Rapid acting and long acting insulin combination formulations | |
| KR102327754B1 (ko) | 안정한 펩티드 제형물 및 제조 방법 | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| HRP20141217T1 (hr) | G-csf tekuä†a formulacija | |
| CA2794929A1 (en) | Concentrated protein formulations and uses thereof | |
| US9636376B2 (en) | Stable compositions of peptide epoxy ketones | |
| KR20050104152A (ko) | 경구용 약물의 흡수를 증진하는 약제학적 조성물 | |
| RU2014141791A (ru) | Режимы дозирования для соединений класса эхинокандинов | |
| KR102541281B1 (ko) | 주사가능한 부프레노르핀 제형 | |
| HRP20140590T1 (hr) | Tekuä†i oblik g-csf konjugata | |
| JP2018188399A (ja) | テリパラチドのプレフィルドシリンジ製剤 | |
| WO2016048189A1 (ru) | Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении |